Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, including serious adverse events and toxicities? Participants will be asked to: 1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen. 2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters. 3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.

NCT Number	NCT07016321
Lead Sponsor	Johns Hopkins University Collaborators: Bharatpur Hospital Chitwan
Conditions	Dengue
Enrollment	600 participants
Start Date	2026-09-01
Primary Completion	2029-03-01 (estimated)
Study Completion	2029-05-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-04